Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer
暂无分享,去创建一个
Virginia G Kaklamani | Soonmyung Paik | Matthew P Goetz | Ingrid A Mayer | Matthew J Ellis | Daniel F Hayes | J. Olson | M. Ellis | R. Gray | T. Whelan | G. Sledge | S. Paik | C. Geyer | M. Goetz | S. Badve | J. Sparano | D. Hayes | P. Ravdin | W. Wood | J. Abrams | K. Albain | E. Dees | D. Toppmeyer | M. Keane | K. Pritchard | A. Brufsky | T. Saphner | I. Mayer | T. Lively | J. Berenberg | V. Kaklamani | L. Wagner | Sunil S Badve | Timothy J Whelan | Kathleen I Pritchard | George W Sledge | Tracy Lively | William C Wood | D. Makower | H. G. Gomez Moreno | P. Reddy | T. Goggins | Joseph A Sparano | Peter M Ravdin | Charles E Geyer | Lynne I Wagner | Adam M Brufsky | Robert J Gray | Kathy S Albain | John A Olson | Della F Makower | Elizabeth C Dees | Thomas J Saphner | Maccon M Keane | Henry L Gomez Moreno | Pavan S Reddy | Timothy F Goggins | Deborah L Toppmeyer | Jeffrey L Berenberg | Jeffrey Abrams
[1] B Fisher,et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.
[2] R. Gray,et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. , 2003, The New England journal of medicine.
[3] L. Garrison,et al. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). , 2012, Contemporary clinical trials.
[4] N. Howlader,et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study , 2016, npj Breast Cancer.
[5] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Andreas Makris,et al. Clinical utility of gene-expression signatures in early stage breast cancer , 2017, Nature Reviews Clinical Oncology.
[7] A. Giobbie-Hurder,et al. Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.
[8] S. Paik,et al. Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B Fisher,et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.
[10] C K Osborne,et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.
[11] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[12] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[13] J M Lachin,et al. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. , 1986, Biometrics.
[14] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[15] R. Gray,et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Jagsi,et al. Recent Trends in Chemotherapy Use and Oncologists’ Treatment Recommendations for Early-Stage Breast Cancer , 2018, Journal of the National Cancer Institute.
[17] E. Perez,et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.
[18] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[19] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[20] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[21] J. Donovan,et al. Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[22] Oguzhan Alagoz,et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. , 2014, Journal of the National Cancer Institute.
[23] Ian Krop,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[26] C. Begg,et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. , 2008, Journal of the National Cancer Institute.
[27] R. Peto,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.
[28] J. J. M. Hoeven. [70-Gene signature as an aid to treatment decisions in early-stage breast cancer]. , 2017 .
[29] J. Abrams. Adjuvant therapy for breast cancer — results from the USA consensus conference , 2001, Breast cancer.
[30] A. Jemal,et al. Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[31] Qing Liu,et al. The importance of systemic therapy in minimizing local recurrence after breast‐conserving surgery: The NSABP experience , 2014, Journal of surgical oncology.
[32] S. Shak,et al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry , 2017, npj Breast Cancer.
[33] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Winer,et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.